Table 1 Mean baseline characteristics of the patients
|  | Overall n = 161 | Low 1,5-AG group < 14.0 μg/mL n = 45 | High 1,5-AG group ≥ 14.0 µg/mL n = 116 | p value |
|---|---|---|---|---|
1,5-Anhydro-d-glucitol, μg/mLa | 17.6 [13.4, 23.3] | 11.0 [8.6, 12.5] | 20.6 [17.3, 25.5] | < 0.0001 |
Age, years | 64.9 ± 11.2 | 66.3 ± 10.6 | 64.4 ± 11.4 | 0.35 |
Male (%) | 139 (86.3) | 38 (84.4) | 101 (87.1) | 0.66 |
Body mass index, kg/m2 | 24.8 ± 3.7 | 24.8 ± 3.7 | 24.8 ± 3.8 | 0.96 |
Hypertension (%) | 111 (68.9) | 31 (68.9) | 80 (69.0) | 0.99 |
Diabetes (%) | 32 (19.9) | 16 (35.6) | 16 (13.8) | 0.002 |
Dyslipidemia (%) | 114 (70.8) | 32 (71.1) | 82 (70.7) | 0.96 |
Current smoker (%) | 41 (25.5) | 11 (24.4) | 30 (25.9) | 0.85 |
Family history of coronary artery disease (%) | 45 (28.1) | 14 (31.1) | 31 (27.0) | 0.60 |
Acute coronary syndrome presentation | 30 (18.6) | 9 (20.0) | 21 (18.1) | 0.78 |
Oral hypoglycemic drugs | 20 (12.4) | 11 (24.4) | 9 (7.8) | 0.006 |
Metformin (%) | 1 (0.6) | 1 (2.2) | 0 (0.0) | 0.11 |
Sulfonylureas (%) | 5 (3.1) | 5 (11.1) | 0 (0.0) | 0.0003 |
Dipeptidyl peptidase-4 inhibitors (%) | 17 (10.6) | 11 (24.4) | 6 (5.2) | 0.0008 |
Others (%) | 5 (3.1) | 2 (4.4) | 3 (2.6) | 0.56 |
Prior statin use, % | 120 (74.5) | 30 (66.7) | 90 (77.6) | 0.15 |
Low-density lipoprotein cholesterol, mg/dL | 89.0 ± 23.9 | 91.4 ± 23.1 | 88.0 ± 24.3 | 0.46 |
High-density lipoprotein cholesterol, mg/dL | 45.3 ± 12.1 | 44.6 ± 11.8 | 45.6 ± 12.3 | 0.64 |
Triglycerides, mg/dL | 126.6 ± 66.8 | 119.5 ± 67.0 | 129.4 ± 66.8 | 0.40 |
Hemoglobin A1c, % | 5.9 ± 0.4 | 6.0 ± 0.5 | 5.8 ± 0.4 | 0.10 |
Fasting blood glucose, mg/dL | 97.3 ± 19.0 | 106.6 ± 25.8 | 93.7 ± 14.2 | < 0.0001 |
High-sensitivity C-reactive protein, mg/dLa | 0.05 [0.02, 0.13] | 0.05 [0.02, 0.12] | 0.05 [0.03, 0.15] | 0.54 |
Estimated glomerular filtration rate, mL/min/1.73 m2 | 83.5 ± 17.9 | 85.1 ± 19.8 | 82.9 ± 17.2 | 0.48 |